Cited by 1,730Renal cell carcinoma treatmentEar and Head TumorsCancer, Hypoxia, and Metabolism

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Mutations of the VHL tumour suppressor gene in renal carcinoma

Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D.R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N.H., Grossman, H.B., Brauch, H., Pomer, S., Brooks, J.D., Isaacs, W.B., Lerman, M.I., Zbar, B., Linehan, W.M.·1994·Nature Genetics

DOI 10.1038/ng0594-85

Open this paper in CoChat — free account

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Integrity signals

Registry

Crossref · 10.1038/ng0594-85

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J. R., Yao, M., Duh, F.-M. C., Orcutt, M. L., Stackhouse, T. M., Kuzmin, I., Modi, W. S., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,971
Self-citation
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (1969) · The Journal of Urology · doi:10.1016/s0022-5347(17)62331-0 · Cited by 1,303
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P. J., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,298
Hereditary cancer, oncogenes, and antioncogenes.
Knudson, A. G. (1985) · PubMed · Cited by 1,218
The Results of Radical Nephrectomy for Renal Cell Carcinoma
Robson, C. J., Churchill, B. M., & Anderson, W. D. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.10.095 · Cited by 1,160
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Höppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,143
Diseases of the kidney
Strauss, M. B., & Welt, L. G. (1963) · Little, Brown eBooks · Cited by 823
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul‐Feketé, C., Ponder, B. A. J., & Münnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 746
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 698
Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
Mulligan, L. M., Eng, C., Healey, C. S., Clayton, D. G., Kwok, J. B., Gardner, E., Ponder, M. A., Frilling, A., Jackson, C. E., Lehnert, H., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-70 · Cited by 643

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

Glenn, G.M., Choyke, P.L., Zbar, B. & Linehan, W.M. von Hippel-Lindau disease: clinical review and molecular genetics. Problems Urol. 4, 312–330 (1990).

Sorted by citations

Items 401–500 of 1,002

Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Cowman, S. J., Fuja, D. G., Liu, X.-D., Tidwell, R. S. S., Kandula, N., Sirohi, D., Agarwal, A. M., Emerson, L. L., Tripp, S. R., Mohlman, J. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3890 · Cited by 76
MUTATION OF THE VON HIPPEL-LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM
Oberstraß, J., Reifenberger, G., REIFENBERGER, J., Wechsler, W., & Collins, V. P. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199606)179:2 · Cited by 76
Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma.
Sükösd, F., Kuroda, N., Beöthe, T., Kaur, A. P., & Kovács, G. (2003) · PubMed · Cited by 76
Hypoxia Inactivates the VHL Tumor Suppressor through PIASy-Mediated SUMO Modification
Cai, Q., Verma, S. C., Kumar, P., Ma, M., & Robertson, E. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009720 · Cited by 76
Renal cell carcinoma risk in type 2 von Hippel–Lindau disease correlates with defects in pVHL stability and HIF-1α interactions
Knauth, K., Bex, C., Jemth, P., & Buchberger, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209062 · Cited by 77
High‐resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma
Yoshimoto, T., Matsuura, K., Karnan, S., Tagawa, H., Nakada, C., Tanigawa, M., Tsukamoto, Y., Uchida, T., Kashima, K., Akizuki, S., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2239 · Cited by 76
Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers
Signoretti, S., Flaifel, A., Chen, Y., & Reuter, V. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2259 · Cited by 76
Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes
Maeurer, M. J., Martin, D. M., Castelli, C., Elder, E. M., Leder, G. H., Storkus, W. J., & Lotze, M. T. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01527407 · Cited by 76
Gramicidin A: A New Mission for an Old Antibiotic
David, J. M., & Rajasekaran, A. K. (2015) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.2015.21 · Cited by 77
The Surgical Approach to Multifocal Renal Cancers: Hereditary Syndromes, Ipsilateral Multifocality, and Bilateral Tumors
Shuch, B. M., Singer, E. A., & Bratslavsky, G. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.01.006 · Cited by 78
Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
Kamrava, M. R., Bernstein, M. B., Camphausen, K. A., & Hodge, J. W. (2009) · Molecular BioSystems · doi:10.1039/b911313b · Cited by 75
The von Hippel–Lindau tumour suppressor protein: new perspectives
Ohh, M., & Kaelin, W. G. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01481-1 · Cited by 75
VON HIPPEL–LINDAU DISEASE
Aronow, M. E., Wiley, H. E., Gaudric, A., Krivosic, V., Gorin, M. B., Shields, C. L., Shields, J. A., Jonasch, E. W., Singh, A. D., & Chew, E. Y. (2019) · Retina · doi:10.1097/iae.0000000000002555 · Cited by 74
miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma
Xiang, W., He, J., Huang, C., Chen, L., Tao, D., Wu, X., Wang, M., Luo, G., Xiao, X., Zeng, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2926 · Cited by 77
VHL-gene Deletion in Single Renal Tubular Epithelial Cells and Renal Tubular Cysts: Further Evidence for a Cyst-dependent Progression Pathway of Clear Cell Renal Carcinoma in von Hippel-Lindau Disease
Montani, M., Heinimann, K., von Teichman, A., Rudolph, T. J., Perren, A. A., & Moch, H. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ddf54d · Cited by 74
Induction of human endometrial cancer cell senescence through modulation of HIF‐1α activity by EGLN1
Kato, H., Inoue, T., Asanoma, K., Nishimura, C., Matsuda, T., & Wake, N. (2005) · International Journal of Cancer · doi:10.1002/ijc.21488 · Cited by 74
Diagnosis of Renal Cancer by Molecular Urinalysis
Eisenberger, C. F., Schoenberg, M., Enger, C. L., HORTOPAN, S. C., Shah, S., Chow, N. ‐., Marshall, F. F., & Sidransky, D. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.23.2028 · Cited by 74
65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma
Neumann, H. P. H., Young, W. F., Krauß, T., Bayley, J., Schiavi, F., Opocher, G., Boedeker, C. C., Tirosh, A., Castinetti, F., Ruf, J., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0085 · Cited by 73
The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma
Sufan, R. I., Jewett, M. A. S., & Ohh, M. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00424.2003 · Cited by 73
Unique Patterns of Allelic Imbalance Distinguish Type 1 from Type 2 Sporadic Papillary Renal Cell Carcinoma
Sanders, M. E., Mick, R., Tomaszewski, J. E., & Barr, F. G. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64260-5 · Cited by 73
Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma
Oosterwijk‐Wakka, J. C., Boerman, O. C., Mulders, P., & Oosterwijk, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611402 · Cited by 73
Sorafenib: delivering a targeted drug to the right targets
Flaherty, K. T. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.5.617 · Cited by 73
The Role of Elongin BC-Containing Ubiquitin Ligases
Okumura, F., Matsuzaki, M., Nakatsukasa, K., & Kamura, T. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00010 · Cited by 80
Analysis of the Birt–Hogg–Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer
da Silva, N. F., Gentle, D., Hesson, L. B., Morton, D. G., Latif, F., & Maher, E. R. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.11.820 · Cited by 73
Self-citation
Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu, M. Y., Poellinger, L., & Walker, C. L. (2003) · PubMed · Cited by 73
Expression of the Ammonia Transporter, Rh C Glycoprotein, in Normal and Neoplastic Human Kidney
Han, K., Croker, B. P., Clapp, W. L., Werner, D., Sahni, M., Kim, J., Kim, H. Y., Handlogten, M. E., & Weiner, I. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020160 · Cited by 73
Genetic and Epigenetic Alterations in the von Hippel-Lindau Gene: the Influence on Renal Cancer Prognosis
Smits, K. M., Schouten, L. J., van Dijk, B. A. C., de Kaa, C. A. H., Wouters, K. A. D., Oosterwijk, E., van Engeland, M., & van den Brandt, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1753 · Cited by 73
An Alternative Route for Multistep Tumorigenesis in a Novel Case of Hereditary Renal Cell Cancer and a t(2;3)(q35;q21) Chromosome Translocation
Bodmer, D., Eleveld, M. J., Ligtenberg, M. J. L., Weterman, M. A. J., Janssen, B. A. P., Smeets, D., de Wit, P. E. J., van den Berg, A., van den Berg, E., Koolen, M. I., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301888 · Cited by 73
Renal cancer in von Hippel–Lindau disease and related syndromes
Bausch, B., Jilg, C. A., Gläsker, S., Vortmeyer, A. O., Lützen, N., Anton, A., Eng, C., & Neumann, H. P. H. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.144 · Cited by 73
The Role of DNA Methylation in Renal Cell Carcinoma
Lasseigne, B. N., & Brooks, J. D. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0337-9 · Cited by 75
Self-citation
Ubiquitin Pathway in VHL Cancer Syndrome
Ohh, M. (2006) · Neoplasia · doi:10.1593/neo.06442 · Cited by 72
Detecting common copy number variants in high-throughput sequencing data by using JointSLM algorithm
Magi, A., Benelli, M., Yoon, S. C., Roviello, F., & Torricelli, F. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr068 · Cited by 72
Insulin-like growth factor-1 signaling in renal cell carcinoma
Tracz, A., Szczylik, C. A., Porta, C., & Czarnecka, A. M. (2016) · BMC Cancer · doi:10.1186/s12885-016-2437-4 · Cited by 73
Molecular genetics and histopathologic features of adult distal nephron tumors
Polascik, T. J., Bostwick, D. G., & Cairns, P. (2002) · Urology · doi:10.1016/s0090-4295(02)01825-3 · Cited by 72
Cystic Renal Tumors: New Entities and Novel Concepts
Moch, H. (2010) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181d98c9d · Cited by 74
Extraneural Hemangioblastoma
Nonaka, D., Rodriguez‐Canales, J., & Rosaí, J. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180457bfc · Cited by 71
CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma
McRonald, F. E., Morris, M. R., Gentle, D., Winchester, L. M., Baban, D. F., Ragoussis, J., Clarke, N. W., Brown, M. D., Kishida, T., Yao, M., et al. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-31 · Cited by 71
Self-citation
The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma
Lichner, Z., Scorilas, A., White, N. M. A., Girgis, A. H., Rotstein, L., Wiegand, K. C., Latif, A., Chow, C., Huntsman, D. D., & Yousef, G. M. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.007 · Cited by 73
Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma
Takáčová, M., Bartošová, M., Škvarková, L., Zaťovičová, M., Vidličková, I., Csáderová, L., Baráthová, M., Breza, J., Jr., Bujdák, P., Pastorek, J., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.1001 · Cited by 71
Frequency of Von Hippel‐Lindau germline mutations in classic and non‐classic Von Hippel‐Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation‐dependent probe amplification
Hes, F. J., van der Luijt, R. B., Janssen, A., Zewald, R., de Jong, G., Lenders, J. W. M., Links, T., LUYTEN, G., Sijmons, R. H., Eussen, H. J., et al. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00827.x · Cited by 71
Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention
Ball, M. W., An, J. Y., Gomella, P. T., Gautam, R., Ricketts, C. J., Vocke, C. D., Schmidt, L. S., Merino, M. J., Srinivasan, R., Malayeri, A. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02263 · Cited by 71
Self-citation
Management of von Hippel-Lindau Disease: An Interdisciplinary Review
Schmid, S., Gillessen, S., Binet, I., Brändle, M., Engeler, D. S., Greiner, J., Hader, C., Heinimann, K., Kloos, P., Krek, W., et al. (2014) · Oncology Research and Treatment · doi:10.1159/000369362 · Cited by 71
Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma
Lee, S., Garner, E. I. O., Welch, W. R., Berkowitz, R. S., & Mok, S. C. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.03.041 · Cited by 70
Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-κB dependent
An, J., Sun, Y., Fisher, M., & Rettig, M. B. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.727.3.6 · Cited by 70
Molecular Genetics of Familial Renal Cell Carcinoma Syndromes
Cohen, D., & Zhou, M. (2005) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2005.01.003 · Cited by 71
HIF and fumarate hydratase in renal cancer
Sudarshan, S., Linehan, W. M., & Neckers, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603547 · Cited by 70
Self-citation
Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A.
Chen, F., Slife, L., Kishida, T., Mulvihill, J. J., Tisherman, S. E., & Zbar, B. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.8.716 · Cited by 70
Self-citation
ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma
Green, Y. S., Ferreira dos Santos, M. C., Fuja, D. G., Reichert, E. C., Campos, A. R., Cowman, S. J., Acuña Pilarte, K., Kohan, J., Tripp, S. R., Leibold, E. A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02460-1 · Cited by 69
Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
Ballesteros, P. Á., Chamorro, J., Román, M. S., Pozas, J., Santos, V. G. D., Granados, Á. R., Grande, E., Alonso‐Gordoa, T., & Molina‐Cerrillo, J. (2021) · Cancers · doi:10.3390/cancers13235981 · Cited by 74
Associations of Single Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Gene with the Characteristics and Prognosis of Renal Cell Carcinomas
Kawai, Y., Sakano, S., Korenaga, Y., Eguchi, S., & Naito, K. (2007) · European Urology · doi:10.1016/j.eururo.2007.01.073 · Cited by 69
Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma
Morris, M. R., Maina, E. N., Morgan, N. V., Gentle, D., Astuti, D., Moch, H., Kishida, T., Yao, M., Schraml, P., Richards, F. M., et al. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.011767 · Cited by 71
Self-citation
Dysregulation of ubiquitin ligases in cancer
Qi, J., & Ronai, Z. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.09.001 · Cited by 69
Precision medicine from the renal cancer genome
Riazalhosseini, Y., & Lathrop, M. G. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.133 · Cited by 69
Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas
Herbers, J., Schullerus, D., Müller, H., Kenck, C., Chudek, J. T., Weimer, J. P., Bugert, P., & Kovács, G. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199705)19:1 · Cited by 69
Renal cell carcinoma: current status and future directions
Martel, C. L. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00076-8 · Cited by 69
The von Hippel-Lindau tumor suppressor gene
Decker, H. J., Weidt, E. J., & Brieger, J. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00296-8 · Cited by 69
Low Incidence of Point Mutations in H‐, K‐ and N‐ras Oncogenes and p53 Tumor Suppressor Gene in Renal Cell Carcinoma and Peritoneal Mesothelioma of Wistar Rats Induced by Ferric Nitrilotriacetate
Nishiyama, Y., Suwa, H., Okamoto, K., Fukumoto, M., Hiai, H., & Toyokuni, S. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03308.x · Cited by 68
PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma
Walton, J., Lawson, K. A., Prinos, P., Finelli, A., Arrowsmith, C. H., & Ailles, L. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00659-1 · Cited by 74
Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein
Nakamura, E., de Abreu-e-Lima, P. C., Awakura, Y., Inoue, T., Kamoto, T., Ogawa, O., Kotani, H., Manabe, T., Zhang, G., Kondo, K., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050867 · Cited by 68
Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma
Iida, Y. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1406 · Cited by 68
Wnt signaling pathways in urological cancers: past decades and still growing
Majid, S., Saini, S., & Dahiya, R. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-7 · Cited by 71
Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
Hong, M. H., Kim, H. S., Kim, C., Ahn, J. R., Chon, H. J., Shin, S. J., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.2.67 · Cited by 67
Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression
Yang, C., Huntoon, K. M., Ksendzovsky, A., Zhuang, Z., & Lonser, R. R. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.007 · Cited by 69
HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway
Hamilton, M., Young, M., Jang, K., Sauer, S., Neang, V., King, A. T., Girke, T., & Martinez, E. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.022 · Cited by 66
Role of theVHL(von Hippel–Lindau) gene in renal cancer: a multifunctional tumour suppressor
Nyhan, M. J., O’Sullivan, G. C., & McKenna, S. L. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360472 · Cited by 69
Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification
Udager, A. M., & Mehra, R. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0218-ra · Cited by 66
A clinical and molecular genetic analysis of solitary ocular angioma
Webster, A. R., Maher, E. R., Bird, A. C., Gregor, Z. J., & Moore, A. T. (1999) · Ophthalmology · doi:10.1016/s0161-6420(99)90127-6 · Cited by 66
Clinical features and molecular genetics of Von Hippel-Lindau disease
Maher, E. R., Webster, A. R., & Moore, A. T. (1995) · Ophthalmic Genetics · doi:10.3109/13816819509059966 · Cited by 66
Studying Cancer Families to Identify Kidney Cancer Genes
Zbar, B., Klausner, R. D., & Linehan, W. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152514 · Cited by 66
Self-citation
Tracheal development and the von Hippel–Lindau tumor suppressor homolog in Drosophila
Adryan, B., Decker, H.-J. H., Papas, T. S., & Hsu, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203611 · Cited by 66
Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy
Pfaffenroth, E. C., & Linehan, W. M. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.779 · Cited by 67
Self-citation
RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis
Peters, I., Rehmet, K., Wilke, N., Kuczyk, M. A., Hennenlotter, J., Eilers, T., Machtens, S. A., Udo Jonas, A., & Serth, J. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-49 · Cited by 65
Nitric oxide and hypoxia
Galkin, A. S., Higgs, A., & Moncada, S. (2007) · Essays in Biochemistry · doi:10.1042/bse0430029 · Cited by 66
THSD7A expression in human cancer
Stahl, P. R., Hoxha, E., Wiech, T., Schröder, C., Simon, R., & Stahl, R. A. K. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22440 · Cited by 65
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
Matsuki, M., Adachi, Y., Ozawa, Y., Kimura, T., Hoshi, T., Okamoto, K., Tohyama, O., Mitsuhashi, K. O., Yamaguchi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13169 · Cited by 65
Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma
Mehdi, A., & Riazalhosseini, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081774 · Cited by 68
Von Hippel Lindau Syndrome
Kim, J., Rini, B. I., & Hansel, D. E. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_22 · Cited by 64
Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells
Honma, M. (2005) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20113 · Cited by 64
VEGF-Targeted Therapy in Metastatic Renal Cell Carcinoma
Rini, B. I. (2005) · The Oncologist · doi:10.1634/theoncologist.10-3-191 · Cited by 64
Retracted
Demonstration of Insulin production and storage in insulinomas by in situ hybridisation and immunocytochemistry
McKenzie, K. J., Hind, C., Farquharson, M. A., McGill, M. J., & Foulis, A. K. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199702)181:2 · Cited by 8
Tumor Suppressor von Hippel-Lindau (VHL) Stabilization of Jade-1 Protein Occurs through Plant Homeodomains and Is VHL Mutation Dependent
Zhou, M. I., Wang, H., Foy, R. L., Ross, J. J., & Cohen, H. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0884 · Cited by 64
Family history and risk of renal cell carcinoma.
Gago-Domínguez, M., Yuan, J., Castelao, J. E., Ross, R. K., & Yu, M. C. (2001) · PubMed · Cited by 64
Mechanisms of Disease: hereditary leiomyomatosis and renal cell cancer—a distinct form of hereditary kidney cancer
Sudarshan, S., Pinto, P. A., Neckers, L., & Linehan, W. M. (2007) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0711 · Cited by 63
Self-citation
Recent advances in the treatment of metastatic renal cell carcinoma
Abe, H., & Kamai, T. (2013) · International Journal of Urology · doi:10.1111/iju.12187 · Cited by 64
Downregulation of Cap43 gene by von Hippel‐Lindau tumor suppressor protein in human renal cancer cells
Masuda, K., Ono, M., Okamoto, M., Morikawa, W., Otsubo, M., Migita, T., Tsuneyoshi, M., Okuda, H., Shuin, T., Naito, S., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11152 · Cited by 63
VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma
von Teichman, A., Compérat, É., Behnke, S., Storz, M., Moch, H., & Schraml, P. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.222 · Cited by 63
Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses)
Hes, F. J., & Feldberg, M. A. M. (1999) · European Radiology · doi:10.1007/s003300050717 · Cited by 63
The Von Hippel-Lindau Protein Interacts with Heteronuclear Ribonucleoprotein A2 and Regulates Its Expression
Pioli, P. A., & Rigby, W. F. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105391200 · Cited by 63
Loss of heterozygosity on the short arm of chromosomes 1 and 3 in sporadic pheochromocytoma and extra-adrenal paraganglioma
Vargas, M. P., Zhuang, Z., Wang, C., Vortmeyer, A. O., Linehan, W. M., & Merino, M. J. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90028-9 · Cited by 63
Self-citation
Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response
Eibl, B., Ebner, S., Duba, C., Böck, G., Romani, N., Erdel, M., Gächter, A., Niederwieser, D. W., & Schuler, G. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199711)20:3 · Cited by 97
Circular RNA hsa_circ_001895 serves as a sponge of microRNA‐296‐5p to promote clear cell renal cell carcinoma progression by regulating SOX12
Chen, Z., Xiao, K., Chen, S., Huang, Z., Ye, Y., & Chen, T. (2019) · Cancer Science · doi:10.1111/cas.14261 · Cited by 62
4-Pyridylanilinothiazoles That Selectively Target von Hippel−Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death
Hay, M. P., Turcotte, S., Flanagan, J. U., Bonnet, M., Chan, D. A., Sutphin, P. D., Nguyen, P., Giaccia, A. J., & Denny, W. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901457w · Cited by 62
Update on the Medical Treatment of Metastatic Renal Cell Carcinoma
Ravaud, A., Wallerand, H., Culine, S., Bernhard, J., Fergelot, P., Bensalah, K., & Patard, J. (2008) · European Urology · doi:10.1016/j.eururo.2008.04.056 · Cited by 62
Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene
Cybulski, C., Krzystolik, K., Murgia, A., Górski, B., Dębniak, T., Jakubowska, A., Martella, M., Kurzawski, G., Prost, M., Kojder, I., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.e38 · Cited by 62
The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B
Huebner, K., Hadaczek, P., Siprashvili, Z., Druck, T., & Croce, C. M. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00009-7 · Cited by 62
Regulation of spindle and kinetochore‐associated protein 1 by antitumor miR‐10a‐5p in renal cell carcinoma
Arai, T., Okato, A., Kojima, S., Idichi, T., Koshizuka, K., Kurozumi, A., Kato, M., Yamazaki, K., Ishida, Y., Naya, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13331 · Cited by 61
SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12
González-Rodríguez, P., Engskog‐Vlachos, P., Zhang, H., Murgoci, A., Zerdes, I., & Joseph, B. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2266-x · Cited by 65
11q13 Allelic Imbalance Discriminates Pulmonary Carcinoids from Tumorlets
Finkelstein, S. D., Hasegawa, T., Colby, T. V., & Yousem, S. A. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65159-0 · Cited by 61
Mechanisms governing target search and binding dynamics of hypoxia-inducible factors
Chen, Y., Cattoglio, C., Dailey, G. M., Zhu, Q., Tjian, R., & Darzacq, X. (2022) · eLife · doi:10.7554/elife.75064 · Cited by 60
The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors
Ye, L., Santarpia, L., & Gagel, R. F. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0031 · Cited by 61

Authors: Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., Lubensky, I., Duan, D. R., Florence, C., Pozzatti, R., Walther, M. M., Bander, N. H., Grossman, H. B., Brauch, H., Pomer, S., Brooks, J. D., Isaacs, W. B., Lerman, M. I., Zbar, B., & Linehan, W. M.
Affiliations: National Cancer Institute (US)
Frederick National Laboratory for Cancer Research (US)
National Institutes of Health (US)
Cornell University (US)
University of Michigan (US)
Technical University of Munich (DE)
Heidelberg University (DE)
Johns Hopkins University (US)
ORCID: Gnarra, J.R.
Schmidt, L.
Wei, M.H.
Lubensky, I.
Bander, N.H.
Brauch, H.
Brooks, J.D.
Isaacs, W.B.
Lerman, M.I.
Linehan, W.M.
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 1994-05
Volume: 7
Issue: 1
Pages: 85-90
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng0594-85
OpenAlex: W2010160635
Cited by: 1,730
References: 29
Citations by year: 2026: 17 · 2025: 25 · 2024: 30 · 2023: 38 · 2022: 38 · 2021: 45 · 2020: 56 · 2019: 47 · 2018: 45 · 2017: 42 · 2016: 57 · 2015: 35 · 2014: 70 · 2013: 66 · 2012: 62
FWCI: 61.77
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Health Sciences › Medicine › Oncology › Ear and Head Tumors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords: VHL gene, von Hippel-Lindau disease, renal carcinoma, clear cell renal cell carcinoma, loss of heterozygosity
MeSH terms: Base Sequence, Carcinoma, DNA Mutational Analysis, DNA, Neoplasm, von Hippel-Lindau Disease, Humans, Kidney Neoplasms, Molecular Sequence Data, Mutation, Organ Specificity, Polymorphism, Restriction Fragment Length, Genes, Tumor Suppressor, Neoplasms, Second Primary, Sequence Deletion, Adenocarcinoma, Clear Cell

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutations of the VHL tumour suppressor gene in renal carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks